Neurix was established in 2011 by Prof. Karl-Heinz Krause as a University of Geneva spin-off, the company maintains its focus on studying neurodegenerative diseases and other related brain disorders using its in-house MiniBrain™ technology. Since incorporation, the company has received over one million euros in European research grants that allowed it to develop several neurodegenerative disease models, namely, Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis.

Neurix’s has been fine-tuning its know-how in 3D neural cultures for over a decade, which include the development of neurospheres (relatively high-throughput) and the MiniBrains™ (larger organoids, low-medium throughput). Our team has developed in-house differentiation protocols to obtain well-characterised 2D and 3D neural cultures from human pluripotent stem cells. The production of our human brain 3D tissues is scalable and reproducible. We provide custom services to fit different research goals (drug testing, biomarker research, or disease modelling). We can functionally analyse neurospheres through multi-electrode array electrophysiology and Ca2+ imaging. There are also a wide range of other assays available (e.g. histology, immunocytochemistry, RNA-seq, single cell RNA-seq). In addition, Neurix provides services around human 3D models of neurodegenerative diseases.